FDA has recently revised Form 356h: Application to Market a New or Abbreviated New Drug or Biologic for Human Use and Form 1571: Investigational New Drug Application (IND) to align with FDA User Fee requirements as well as make other improvements to data quality and ease of use.
These forms are required to be submitted with NDAs, ANDAs, BLAs and INDs. FDA uses this information in the review process and companies should be aware of these updates and are required to use the most current version of these forms.
Companies need to use the most recent update to Forms 356h and 1571 in their submissions.
View referenced article
Author(s)
Related Insights
March 31, 2026
Foley Viewpoints
Coming Soon to Procurement Contracts – A Contract Clause Prohibiting Certain DEI Activities
On March 26, 2026, the President issued Executive Order 14398 titled “Addressing DEI Discrimination by Federal Contractors.” The Order…
March 30, 2026
Foley Viewpoints
The “But For” Dilemma – How Proposed Texas Public Utility Commission Large Load Interconnection Rules Impact Government Incentives Strategies
Companies seeking governmental incentives for expansion or relocation projects, such as tax abatements or state-level grants, must…
March 25, 2026
Foley Viewpoints
NAIC Spring 2026 Meeting Update: Homeowners Market Data Call (C) Task Force
Summary and Takeaways: The Homeowners Market Data Call (C) Task Force provided an update on the remaining implementation steps for the…